|
Jul 22
|
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
|
|
Jul 16
|
Hengrui and Kailera report positive data from Phase III obesity treatment trial
|
|
Jul 15
|
Lilly’s Zepbound Faces a Potential Weight-Loss Rival. It’s Made by a Chinese Biotech.
|
|
Jul 15
|
Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
|
|
Jul 15
|
Hengrui, Kailera say dual-acting obesity shot succeeds in China study
|
|
Jul 13
|
China Biotech’s Stunning Advance Is Changing the World’s Drug Pipeline
|
|
Dec 30
|
IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849
|
|
Dec 29
|
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
|